304 related articles for article (PubMed ID: 12542895)
81. [Determination of malondialdehyde-modified LDL(MDA-LDL) and its potential usefulness].
Kotani K; Kondo A; Manabe M; Maekawa M; Kanno T
Rinsho Byori; 1997 Jan; 45(1):47-54. PubMed ID: 9022342
[TBL] [Abstract][Full Text] [Related]
82. Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis.
Bui MN; Sack MN; Moutsatsos G; Lu DY; Katz P; McCown R; Breall JA; Rackley CE
Am Heart J; 1996 Apr; 131(4):663-7. PubMed ID: 8721636
[TBL] [Abstract][Full Text] [Related]
83. The low-density lipoprotein (LDL)-associated PAF-acetylhydrolase activity and the extent of LDL oxidation are important determinants of the autoantibody titers against oxidized LDL in patients with coronary artery disease.
Lourida ES; Papathanasiou AI; Goudevenos JA; Tselepis AD
Prostaglandins Leukot Essent Fatty Acids; 2006 Aug; 75(2):117-26. PubMed ID: 16843649
[TBL] [Abstract][Full Text] [Related]
84. High levels of IgM against methylglyoxal-modified apolipoprotein B100 are associated with less coronary artery calcification in patients with type 2 diabetes.
Engelbertsen D; Anand DV; Fredrikson GN; Hopkins D; Corder R; Shah PK; Lahiri A; Nilsson J; Bengtsson E
J Intern Med; 2012 Jan; 271(1):82-9. PubMed ID: 21668821
[TBL] [Abstract][Full Text] [Related]
85. Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis.
Vuilleumier N; Bas S; Pagano S; Montecucco F; Guerne PA; Finckh A; Lovis C; Mach F; Hochstrasser D; Roux-Lombard P; Gabay C
Arthritis Rheum; 2010 Sep; 62(9):2640-50. PubMed ID: 20506304
[TBL] [Abstract][Full Text] [Related]
86. Plasma levels of antibodies against oxidized LDL are inherited but not associated with HDL-cholesterol level in families with early coronary heart disease.
Paavola T; Kangas-Kontio T; Salonurmi T; Kuusisto S; Huusko T; Savolainen MJ; Kakko S
Atherosclerosis; 2012 Sep; 224(1):123-8. PubMed ID: 22818623
[TBL] [Abstract][Full Text] [Related]
87. Autoantibodies against malondialdehyde-modified LDL are elevated in subjects with an LDL subclass pattern B.
Jansen H; Ghanem H; Kuypers JH; Birkenhäger JC
Atherosclerosis; 1995 Jun; 115(2):255-62. PubMed ID: 7661884
[TBL] [Abstract][Full Text] [Related]
88. [Autoantibodies against oxidised low density lipoproteins in patients with coronary disease].
Maggi E; Perani G; Falaschi F; Frattoni A; Martignoni A; Finardi G; Stefano PL; Simeone F; Paolini G; DeVecchi E
Presse Med; 1994 Jul 2-9; 23(25):1158-62. PubMed ID: 7971845
[TBL] [Abstract][Full Text] [Related]
89. Comparison of laboratory parameters as risk factors for the presence and the extent of coronary or carotid atherosclerosis: the significance of apolipoprotein B to apolipoprotein all ratio.
Cerne D; Ledinski G; Kager G; Greilberger J; Wang X; Jürgens G
Clin Chem Lab Med; 2000 Jun; 38(6):529-38. PubMed ID: 10987202
[TBL] [Abstract][Full Text] [Related]
90. Characteristics of Lipoprotein(a)-Containing Circulating Immune Complexes as Markers of Coronary Heart Disease.
Klesareva EA; Afanas'eva OI; Donskikh VV; Adamova IY; Pokrovskii SN
Bull Exp Biol Med; 2016 Dec; 162(2):231-236. PubMed ID: 27905032
[TBL] [Abstract][Full Text] [Related]
91. [Oxidized LDL in patients with coronary heart disease and normal subjects].
Hasegawa A; Toshima S; Nakano A; Nagai R
Nihon Rinsho; 1999 Dec; 57(12):2754-8. PubMed ID: 10638208
[TBL] [Abstract][Full Text] [Related]
92. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes.
Tsimikas S; Bergmark C; Beyer RW; Patel R; Pattison J; Miller E; Juliano J; Witztum JL
J Am Coll Cardiol; 2003 Feb; 41(3):360-70. PubMed ID: 12575961
[TBL] [Abstract][Full Text] [Related]
93. Investigation of MDA-LDL (malondialdehyde-modified low-density lipoprotein) as a prognostic marker for coronary artery disease in patients with type 2 diabetes mellitus.
Kotani K; Tashiro J; Yamazaki K; Nakamura Y; Miyazaki A; Bujo H; Saito Y; Kanno T; Maekawa M
Clin Chim Acta; 2015 Oct; 450():145-50. PubMed ID: 26265234
[TBL] [Abstract][Full Text] [Related]
94. Circulating oxidized low density lipoprotein, autoantibodies against them and homocysteine serum levels in diagnosis and estimation of severity of coronary artery disease.
Faviou E; Vourli G; Nounopoulos C; Zachari A; Dionyssiou-Asteriou A
Free Radic Res; 2005 Apr; 39(4):419-29. PubMed ID: 16028367
[TBL] [Abstract][Full Text] [Related]
95. Relationship between oxidized LDL, IgM, and IgG autoantibodies to ox-LDL levels with recurrent cardiovascular events in Swedish patients with previous myocardial infarction.
Crisby M; Henareh L; Agewall S
Angiology; 2014 Nov; 65(10):932-6. PubMed ID: 24288363
[TBL] [Abstract][Full Text] [Related]
96. Oxidized LDL autoantibodies are related to apolipoprotein E phenotype, independently of postprandial change in plasma triglycerides and LDL size, among patients with angiographically verified coronary artery disease and healthy controls.
Metso S; Nikkilä M; Laippala P; Jaakkola O; Solakivi T; Lehtimäki T
J Biomed Sci; 2003; 10(3):345-51. PubMed ID: 12711862
[TBL] [Abstract][Full Text] [Related]
97. Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease.
Inoue T; Uchida T; Kamishirado H; Takayanagi K; Hayashi T; Morooka S
J Am Coll Cardiol; 2001 Mar; 37(3):775-9. PubMed ID: 11693751
[TBL] [Abstract][Full Text] [Related]
98. Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis.
Parums DV; Brown DL; Mitchinson MJ
Arch Pathol Lab Med; 1990 Apr; 114(4):383-7. PubMed ID: 2322097
[TBL] [Abstract][Full Text] [Related]
99. [Antibodies against modified low-density lipoproteins and their complexes in blood of patients with various manifestations of atherosclerosis].
Belik IV; Ivantsova AA; Mamedova ZE; Denisenko AD
Biomed Khim; 2016 May; 62(4):471-5. PubMed ID: 27563003
[TBL] [Abstract][Full Text] [Related]
100. Evaluation of oxidized low-density lipoprotein in the coronary circulation of patients with coronary artery disease, and its association with percutaneous coronary intervention.
Ramadan MM; Kodama M; Hirono S; Okura Y; Mitsuma W; Ito M; Aizawa Y
Int J Cardiol; 2009 May; 134(3):e117-9. PubMed ID: 18486249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
